Sirnaomics
Sirnaomics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for critical human diseases through RNA interference (RNAi) technologies. The company focuses on oncology, anti-fibrotic treatments, and viral infections, leveraging its proprietary Polypeptide Nano-Particle (PNP) technology for effective small interfering RNA (siRNA) drug delivery. Sirnaomics has several product candidates, including STP705 for scar reduction and liver fibrosis, STP909 for colon cancer, and STP602 for Zika virus. Founded in 2007, the company operates from its headquarters in Gaithersburg, Maryland, with additional facilities in Cambridge, Massachusetts, and China. Sirnaomics is strategically partnered with Precision NanoSystems Inc. to enhance its development capabilities.
Baisios is a developer of tumor immune cell therapy technology and is dedicated to the growth of the tumor biotherapy industry.
EDIRNA is an innovative biotech company focused on RNA-Editing technology discovers and develops edit-to cure therapeutics for undruggable target conditions.
RNAimmune, Inc. is a biopharmaceutical company focused on the development of messenger RNA (mRNA) therapeutics and vaccines. Based in Gaithersburg, Maryland, the company utilizes mRNA as a data carrier to instruct the human body to produce proteins that combat a variety of diseases, including cancer, viral infections, and rare diseases. RNAimmune has developed an mRNA design platform and self-amplifying mRNA technology, alongside a proprietary artificial intelligence algorithm known as ALEPVA, which aids in antigen prediction and vaccine design. The company is a spin-off from Sirnaomics, Inc. and holds exclusive rights to the Polypeptide Lipid Nanoparticle (PLNP) technology for mRNA delivery. By integrating these innovative technologies, RNAimmune aims to create a robust platform for mRNA drug discovery and development, addressing significant unmet medical needs in the industry.
RNAimmune, Inc. is a biopharmaceutical company focused on the development of messenger RNA (mRNA) therapeutics and vaccines. Based in Gaithersburg, Maryland, the company utilizes mRNA as a data carrier to instruct the human body to produce proteins that combat a variety of diseases, including cancer, viral infections, and rare diseases. RNAimmune has developed an mRNA design platform and self-amplifying mRNA technology, alongside a proprietary artificial intelligence algorithm known as ALEPVA, which aids in antigen prediction and vaccine design. The company is a spin-off from Sirnaomics, Inc. and holds exclusive rights to the Polypeptide Lipid Nanoparticle (PLNP) technology for mRNA delivery. By integrating these innovative technologies, RNAimmune aims to create a robust platform for mRNA drug discovery and development, addressing significant unmet medical needs in the industry.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.